Senti Biosciences Inc
For the period ended Mar 31, 2024. Filed May 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 9, 2024
SNTI$0.14-11.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share data)
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Revenue | ||
| Contract revenue | $— | $1,036 |
| Grant income | — | 250 |
| Total revenue | — | 1,286 |
| Operating expenses | ||
| Research and development (included related party cost of $3,632 and $—, respectively) | 8,779 | 7,059 |
| General and administrative | 7,522 | 9,191 |
| Total operating expenses | 16,301 | 16,250 |
| Loss from operations | (16,301) | (14,964) |
| Other income (expense) | ||
| Interest income, net | 331 | 1,061 |
| Change in fair value of contingent earnout liability | — | 59 |
| Change in fair value of GeneFab Note Receivable - related party | 29 | — |
| Change in fair value of GeneFab Economic Share - related party | 55 | — |
| Change in fair value of GeneFab Option - related party | 2,314 | — |
| GeneFab sublease income - related party | 1,461 | — |
| Other income (expense) | — | (8) |
| Total other income, net | 4,190 | 1,112 |
| Net loss from continuing operations | (12,111) | (13,852) |
| Net loss from discontinued operations | — | (4,870) |
| Net loss | (12,111) | (18,722) |
| Other comprehensive gain (loss) | ||
| Unrealized gain on investments | — | 2 |
| Comprehensive loss | $(12,111) | $(18,720) |
| Net loss per share, basic and diluted | ||
| Net loss per share from continuing operations, basic and diluted | $(0.26) | $(0.31) |
| Net loss per share from discontinued operations, basic and diluted | — | (0.11) |
| Net loss per share, basic and diluted | $(0.26) | $(0.42) |
| Weighted-average shares outstanding, basic and diluted | 45,708,601 | 44,070,974 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.